Hippocampus volumen og hukommelsesfunktioner i aneurysmal subaraknoidal blødning
Undersøgelse af forholdet mellem hippocampus volumen og hukommelsesfunktioner hos patienter med aneurysmal subaraknoidal blødning (aSAH)
Neuropsychological and functional long-term consequences of subarachnoid hemorrhages (SAH) represent a great challenge, since sometimes considerable cognitive deficits occur without evidence of substantial brain damage. In this study, we want to examine if the frequently observed memory deficits are associated with hippocampal atrophy.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Long-term or even permanent neuropsychological impairments are frequently observed after aneurysmal subarachnoid hemorrhages (aSAH). Among the most common impairments after aSAH are memory deficits. Volumetric MRI studies suggest an association of memory dysfunctions with temporal atrophy, especially of the hippocampus. In a previous study, 77 patients with good or moderate clinical outcome after aSAH were examined one year after discharge (Bendel et al., 2006). Temporomesial atrophy was detected without direct brain damage, e.g. by secondary ischemia. Due to the effects of complex cognitive impairments on the quality of life and participation in social and professional life, this relationship will be examined in more detail in the planned study. Specifically, we will investigate to what extent the frequently observed discrepancy between severe memory impairment and normal structural imaging results (no focal lesions in temporomesial areas) is due to hippocampal atrophy. In contrast to Bender and colleagues, this question will be investigated in the acute phase of the disease, immediately after admission to inpatient neurological rehabilitation.
Over a period of 24 months, 29 neurological rehabilitation patients with aSAH (Hunt & Hess grade I and II) are going to be included. Within the first week (day 1 to 7) after study enrollment, a native MRI examination (without contrast agent) is performed, in which a high-resolution 3D-MPRAGE sequence (T1 weighting) is measured in the sagittal plane. After checking the data quality of the 3D-MPRAGE sequence, especially with regard to its suitability for hippocampal volume determination, a comprehensive neuropsychological examination is performed, in which specific memory and attentional functions are tested.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Melanie Boltzmann, PhD
- Telefonnummer: 0049 5152 781 256
- E-mail: m.boltzmann@bdh-klinik-hessisch.oldendorf
Undersøgelse Kontakt Backup
- Navn: Simone B Schmidt, PhD
- Telefonnummer: 0049 5152 781 215
- E-mail: si.schmidt@bdh-klinik-hessisch.oldendorf
Studiesteder
-
-
-
Hessisch Oldendorf, Tyskland, 31840
- Rekruttering
- BDH-Clinic Hessisch Oldendorf
-
Kontakt:
- Melanie Boltzmann, PhD
- Telefonnummer: 0049 5152 781 256
- E-mail: m.boltzmann@bdh-klinik-hessisch-oldendorf.de
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
neurological rehabilitation patients with aneurysmal subarachnoid hemorrhage (Hunt & Hess grade I or II)
Beskrivelse
Inclusion Criteria:
- neurological rehabilitation patients in phase B - D
- at minimum eight weeks after disease onset
- aneurysmal subarachnoid hemorrhage (Hunt & Hess grade I or II)
- written consent from the patient's legal representative
- exclusion of pregnancy
Exclusion Criteria:
- insufficient cardiorespiratory stability
- previous brain damage
- mental disorders (dementia, depression)
- colonization with multi-resistant pathogens
- MRI contraindications
- claustrophobia
- weight > 120 kg
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimental group
Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage |
Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured. |
|
Control group
Healthy adults controlled for age, gender and educational status |
Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changed hippocampal volume in aSAB
Tidsramme: 2 weeks
|
Hypothesis: patients have smaller hippocampal volume than healthy control subjects. For the hippocampal volume a structural MRI scan (3D-MPRAGE) is obtained |
2 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changed memory function in aSAB
Tidsramme: 2 weeks
|
Hypothesis: patients have lower scores in the Visual and Verbal memory test (VVM) than healthy control subjects. |
2 weeks
|
|
Influence of the type of therapy on the hippocampal volume
Tidsramme: 2 weeks
|
Hypothesis: hippocampal volumes differ between aSAH patients with surgical or endovascular treatment. |
2 weeks
|
|
Influence of the lesion site on the hippocampal volume
Tidsramme: 2 weeks
|
Hypothesis: there are no differences between ispi- and contralateral hippocampal volumes |
2 weeks
|
|
Interrater reliability
Tidsramme: 2 weeks
|
Hypothesis: It is expected that there will be no difference in the ratings of hippocampal volume between two independent raters. |
2 weeks
|
|
Changed intracranial volume in aSAB
Tidsramme: 2 weeks
|
Hypothesis: patients have smaller intracranial volume than healthy control subjects. |
2 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Jens D Rollnik, MD, BDH-Clinic Hessisch Oldendorf
- Ledende efterforsker: Melanie Boltzmann, PhD, BDH-Clinic Hessisch Oldendorf
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Neuroadfærdsmæssige manifestationer
- Blødning
- Intrakranielle blødninger
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Sygdomme i nervesystemet
- Subaraknoidal blødning
- Hukommelsesforstyrrelser
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- SAB-VOL
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All IPD that underlie results in a publication.
IPD-delingstidsramme
Period of availability begins when results are published, at the earliest in Dec 2022
IPD-delingsadgangskriterier
IPD can be obtained from the principal investigator upon reasonable request.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .